Mutual of America Capital Management LLC Invests $4.62 Million in Elanco Animal Health Incorporated $ELAN

Mutual of America Capital Management LLC acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 229,442 shares of the company’s stock, valued at approximately $4,621,000.

A number of other large investors have also added to or reduced their stakes in ELAN. SJS Investment Consulting Inc. boosted its holdings in Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after acquiring an additional 1,333 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its position in shares of Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after purchasing an additional 900 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after purchasing an additional 951 shares during the last quarter. First Horizon Advisors Inc. boosted its stake in Elanco Animal Health by 184.3% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after purchasing an additional 2,414 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in Elanco Animal Health by 261.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock valued at $58,000 after purchasing an additional 2,922 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

Shares of ELAN opened at $24.22 on Friday. The firm has a fifty day simple moving average of $22.99 and a two-hundred day simple moving average of $20.24. The firm has a market cap of $12.03 billion, a PE ratio of 403.65, a P/E/G ratio of 3.35 and a beta of 1.87. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $25.29.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.13 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.Elanco Animal Health’s revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Piper Sandler raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $24.00 to $30.00 in a report on Thursday, January 22nd. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $18.00 to $24.00 in a report on Tuesday, October 7th. Zacks Research downgraded Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, December 10th. Finally, Morgan Stanley upped their price target on Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average target price of $25.11.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction dated Friday, December 12th. The shares were purchased at an average price of $21.30 per share, for a total transaction of $213,000.00. Following the purchase, the director directly owned 131,773 shares of the company’s stock, valued at approximately $2,806,764.90. This trade represents a 8.21% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Rajeev A. Modi acquired 4,500 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the acquisition, the insider owned 123,082 shares of the company’s stock, valued at $2,625,339.06. The trade was a 3.79% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 43,450 shares of company stock worth $937,883 over the last 90 days. 0.89% of the stock is owned by company insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.